Insight Molecular Diagnostics (IMDX) Accumulated Expenses (2015 - 2026)

Insight Molecular Diagnostics (IMDX) has 12 years of Accumulated Expenses data on file, last reported at $3.3 million in Q1 2026.

• Quarterly Accumulated Expenses rose 198.66% year-over-year to $3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (up 198.66% YoY) and the FY2025 annual result came in at $1.1 million, down 42.44% from the prior year.
• Accumulated Expenses improved to $3.3 million in Q1 2026 per IMDX's latest filing, from $1.1 million in the prior quarter.
• The five-year high for Accumulated Expenses was $4.1 million in Q3 2022, with the low at $1.1 million in Q1 2024.
• Average Accumulated Expenses over 5 years is $2.0 million, with a median of $1.7 million recorded in 2023.
• Year-over-year, Accumulated Expenses slumped 57.66% in 2023 and soared 198.66% in 2026.
• Insight Molecular Diagnostics' Accumulated Expenses stood at $2.0 million in 2022, then retreated by 18.45% to $1.6 million in 2023, then grew by 17.59% to $1.9 million in 2024, then plunged by 42.44% to $1.1 million in 2025, then soared by 198.66% to $3.3 million in 2026.
• Business Quant data shows IMDX's Accumulated Expenses at $3.3 million in Q1 2026, $1.1 million in Q4 2025, and $1.1 million in Q3 2025.